Auris Medical Reports Second Quarter 2018 Financial Results and Provides Business Update
15 août 2018 06h45 HE
|
Auris Medical AG
Dosing in second Phase 1 clinical trial with intranasal betahistine nearing completion Approaching important interactions with regulatory agencies Progressing with strategic repositioning of...
Auris Medical to Report Second Quarter 2018 Financial Results and Provide Business and Update on Wednesday, August 15, 2018
09 août 2018 08h00 HE
|
Auris Medical AG
Zug, Switzerland, August 09, 2018 - Auris Medical Holding AG (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in neurotology...
Auris Medical Prices $7 Million Public Offering
12 juil. 2018 19h59 HE
|
Auris Medical AG
Zug, Switzerland - July 12, 2018 - Auris Medical Holding AG (Nasdaq: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in neurotology...
Auris Medical Announces Publication Confirming Dose-Dependent Effects of Betahistine and Relationship to Bioavailability in Cat Model of Acute Vertigo
03 juil. 2018 08h00 HE
|
Auris Medical AG
Zug, Switzerland, July 3, 2018 - Auris Medical Holding AG (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in neurotology and...
Auris Medical to Host Key Opinion Leader Call Focused on AM-201 Program for Treating Major Side Effects of Antipsychotics on June 11, 2018
30 mai 2018 07h45 HE
|
Auris Medical AG
Zug, Switzerland, May 30, 2018 - Auris Medical Holding AG (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in neurotology and...
Auris Medical Provides Business and Strategy Update and Reports First Quarter 2018 Financial Results
15 mai 2018 06h45 HE
|
Auris Medical AG
Expansion of intranasal betahistine program into mental health supportive care Initiating project AM-201 for the treatment of histaminergic receptor mediated weight gain and drowsiness in...
Auris Medical to Report First Quarter 2018 Financial Results and Provide Business and Strategy Update on Tuesday, May 15, 2018
14 mai 2018 07h30 HE
|
Auris Medical AG
Zug, Switzerland, May 14, 2018 - Auris Medical Holding AG (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in neurotology,...
Auris Medical Receives Positive Scientific Advice from EMA on Development Plan and Regulatory Pathway for AM-111
07 mai 2018 07h30 HE
|
Auris Medical AG
Design for single pivotal phase 3 trial validated by European Medicines Agency Regulatory pathway towards European market approval mapped out Strategy update scheduled together with...
Auris Medical Announces Publication Related to AM-111 in Peer-Reviewed Scientific Journal
04 mai 2018 06h45 HE
|
Auris Medical AG
Zug, Switzerland, May 4, 2018 - Auris Medical Holding AG (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in neurotology,...
Auris Medical Announces Early Repayment of Part of its Loan Facility
09 avr. 2018 06h45 HE
|
Auris Medical AG
Zug, Switzerland, April 9, 2018 - Auris Medical Holding AG (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in neurotology,...